Stock LSTA LISATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lisata Therapeutics, Inc.

Equities

LSTA

US1280583022

Delayed Nasdaq
Other stock markets
 15:16:20 2024-05-03 EDT 		5-day change 1st Jan Change
2.85 USD -2.73% Intraday chart for Lisata Therapeutics, Inc. +7.64% +4.40%
04-23 Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer MT
04-23 Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma CI

Evolution of the average Target Price on Lisata Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ca3072f58f78cd10b.8In3cP8P3Wm4MaznD4dIUJsulfRePO15PxI-QFQ690E.itPEQYl4vwHJVeioX9gCBdJx0qU_WqQRd1NhCBtImAW11rpFuzaPIY9Jzw~397e7e1b5343dd142af3c091a53cdb8d

Analyst Recommendations on Lisata Therapeutics, Inc.

HC Wainwright Adjusts Lisata Therapeutics' Price Target to $15 From $6, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Caladrius Biosciences to $6 From $8, Reiterates Buy Rating MT
CALADRIUS BIOSCIENCES : Chardan Suspends Coverage on Caladrius Biosciences at Buy Rating With $6 Price Target MT
CALADRIUS BIOSCIENCES : Brookline Capital Management Adjusts Caladrius Biosciences PT to $10 From $7, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.93 USD
Average target price
14.5 USD
Spread / Average Target
+394.88%
High Price Target
15 USD
Spread / Highest target
+411.95%
Low Price Target
14 USD
Spread / Lowest Target
+377.82%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lisata Therapeutics, Inc.

HC Wainwright
Chardan
Brookline Capital Management

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LSTA Stock
  4. Consensus Lisata Therapeutics, Inc.